PURPOSE. Activation of complement has been implicated as one of the major causes of age-related macular degeneration (AMD). Evidence is accumulating for a role of complement in other retinal diseases, such as diabetic retinopathy and proliferative vitreoretinopathy. Because of the paucity of animal models that directly investigate the role of complement in retinal pathology, the authors sought to develop a model of increased complement expression and activation, specifically in the murine retina. METHODS. The authors constructed a recombinant adenovirusexpressing murine complement component 3 (C3, AdcmvC3). Adult mice were injected in the subretinal space with either AdcmvC3 or a control virus, AdcmvGFP. After 1 to 2 weeks of exogenous C3 expression, mice were analyzed by scotopic electroretinography and fluorescein angiography. Eyes were harvested for histologic, immunohistochemical, and quantitative RT-PCR analyses. RESULTS. Mice injected with C3-expressing adenovirus exhibited significantly increased vascular permeability, endothelial cell proliferation and migration, RPE atrophy, loss of photoreceptor outer segments, reactive gliosis, retinal detachment, and reduced retinal function relative to those injected with a control adenovirus. Deposition of the membrane attack complex was observed on endothelial cells and photoreceptor outer segments. CONCLUSIONS. Adenovirus-mediated delivery of C3 to murine RPE induces significant functional and anatomic changes that reproduce many of the features of AMD as well as those of other retinal diseases. This novel model may be useful in assessing the role of complement in retinal pathology and in developing anti-complement therapies for retinal diseases associated with complement activation. (Invest Ophthalmol Vis Sci. 2011;52:3436 -3445)
D
ysregulation of the complement system is considered to be one of the major factors contributing to the etiology of age-related macular degeneration (AMD), one of the leading causes of blindness in the elderly. 1 The most devastating form of the disease, which affects approximately 10% of patients, 2 involves the growth of attenuated blood vessels from the choroidal vasculature through Bruch's membrane and into the retina. The plasma released by these "ill-formed" vessels damages photoreceptors and other retinal cells, eventually leading to a severe loss of vision. In the vast majority of AMD patients, however, extracellular deposits called drusen develop between the retinal pigment epithelium (RPE) and Bruch's membrane and eventually lead to atrophy of the RPE (geographic atrophy).
A potential role for complement in AMD was considered when complement proteins were identified in the drusen of AMD eyes. [3] [4] [5] [6] Since then, polymorphisms have been identified in a number of complement genes and have been observed to be either strongly predictive of or protective against AMD. A single amino acid change, Y402H, in factor H may account for as much as 40% to 50% of AMD in aging eyes. [7] [8] [9] Haplotype variants in both factor B and complement component 2 (C2) present a significantly reduced risk for AMD, 10 whereas an R80G substitution in complement C3 may increase the risk to as much as 22%. 11 The factor B (32Q) variant has been shown to have a fourfold lower binding affinity for C3b, with a reduced ability to form the convertase. 12 In addition, polymorphisms in C2, C3, and factor B have been shown to be significantly linked with progression to both types of advanced AMD, choroidal neovascularization, and geographic atrophy. 2, 13, 14 Although most of the evidence for complement-induced retinal pathology has been for AMD, indications of a role for complement activation in other retinal diseases is accumulating. Deposition of complement proteins has been observed in the choriocapillaris of patients with diabetic retinopathy 15 and in the retinal vessels of diabetic subjects. 16 These same vessels exhibited a significant reduction in expression of the complement regulatory proteins CD55 and CD59. Complement components have also been observed in the epiretinal membranes of patients with proliferative vitreoretinopathy (PVR) 17 and upregulation of the classical pathway initiator protein C1q, and altered expression of other proteins of the cascade has been observed in glaucomatous eyes. 18, 19 There are few animal models that directly investigate the role of complement in retinal function and pathology. Most of these have looked at the impact of different complement proteins in the development of laser-induced choroidal neovascularization (CNV) in the mouse retina. Some of these studies 20 -22 have demonstrated the dependence of this pathology on the alternative, rather than classical or lectin, pathway and on the formation of the membrane attack complex (MAC). Others 23 have demonstrated a significant role played by the anaphylatoxins C3a and C5a in the development of CNV. Aged mice with deficiency of factor H 24, 25 exhibit altered architecture in Bruch's membrane, RPE, and photoreceptors, reduced ERGs, and loss of integrity of retinal vessels. The alternative complement pathway has also recently been implicated as a major factor in light-induced retinal degeneration, which has been shown to be significantly reduced in a mouse deficient in factor D. 26 Ganglion cells of C3-deleted mice exhibit transient, but significant, protection from degeneration caused by retinal ischemia reperfusion. 27 Although 1 of 3 distinct pathways-classical, lectin, or alternative-can initiate the complement cascade, 28 all three converge with the breakdown of C3 into its active components, C3a and C3b. This initiates the final part of the pathway that culminates in the formation of the MAC, a porelike structure that inserts in the membranes of self-or non-self cells, causing their lysis. In addition to the potential for cell lysis by the production of the opsonin C3b, the activation of C3 allows for the generation of the anaphylatoxins C3a and C5a, both of which are powerful and pleiotropic effectors of inflammation. Unlike the classical or lectin pathways, the alternative pathway is constantly active with small amounts of C3 hydrolysis and conversion to the convertase occurring in the serum. With the rapidly accumulating evidence implicating complement in a variety of retinal pathologic conditions, we considered it imperative to determine the effects of complement overexpression in the mouse retina. To do this, we elected to study the consequences of an increased local expression of C3 in the mouse retina on retinal anatomy and function. We hypothesized that a local increase in C3 expression would result in a local increase in C3 hydrolysis and conversion to the convertase. We increased the expression of C3 by injection of an adenovirus-expressing murine C3 regulated by the cytomegalovirus (CMV) promoter into the subretinal space. We have shown previously 29 that subretinal administration of a serotype 5 adenovirus containing a CMV-driven transgene results in transgene expression primarily in the RPE. Scotopic electroretinography, fluorescein angiography, and histologic analysis indicates that increased expression of C3 in the murine RPE causes significant functional and anatomic changes in the murine retina.
MATERIALS AND METHODS

Adenovirus Constructs
An MluI fragment from pCMV-Sport6C3 (image clone ID 5134713; American Type Culture Collection, Manassas, VA) containing a murine C3 cDNA was cloned into the MluI site of pShCMVMCS (a modified version of pShuttle containing the CMV promoter, an SV40 intron and polyA, and an MluI-inclusive multiple cloning site; details of this plasmid are available on request). The C3-containing pShuttle was then recombined with pAd-Easy1, and the rescued virus, AdCMVC3, was amplified as previously described. 29 The control virus used in this study, AdCMVGFP, has been previously described (EGFPNAd5 30 ). For Western blot analysis, human embryonic retinoblasts (HERs) were infected with either AdCMVC3 or AdCMVGFP in Dulbecco's modified Eagle's medium supplemented with 2% fetal bovine serum (Invitrogen, Carlsbad, CA). Cell lysate and media were loaded on a 10% Tris-HCl gel (Criterion; Bio-Rad, Hercules, CA). Membrane was probed with an anti-mouse C3 polyclonal antibody (1:1000; Cell Sciences, Canton, MA), followed by a 1:10,000 dilution of horseradish peroxidase-conjugated goat anti-rabbit. For immunocytochemistry, 1.2 ϫ 10 6 HERs were infected at a multiplicity of infection of 600 and fixed with 4% formalin 24 hours after infection. Cells were incubated with a 1:50 dilution of anti-mouse C3 (MP Biomedicals, Solon, OH) followed by a 1:400 dilution of CY3-conjugated donkey anti-goat (Jackson ImmunoResearch Laboratories, West Grove, PA). Cells were imaged using an inverted microscope (IX51; Olympus, Tokyo, Japan) with appropriate filters, a digital camera (Retiga 2000R FAST; QImaging, Vancouver, BC, Canada), and software (QCapture Pro 5.0; QImaging).
Subretinal Administration of Viruses
All experiments involving animals were in conducted accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. C57Bl6/J mice were purchased from Jackson Laboratories (Bar Harbor, ME) and were maintained in 12-hour dark/12-hour light cycles in accordance with federal, state, and local regulations. Injections were performed as previously described. 29 Briefly, mice were anesthetized by intraperitoneal injection of 0.1 mL/10 g ketamine (10 mg/mL)/xylazine (1 mg/mL), followed by application of 1 drop of proparacaine hydrochloride (0.5%) to each eye. Virus particles (2 ϫ 10 9 ) were injected into the subretinal space of 6-to 8-week-old C57Bl6/J male mice using a transscleral/transchoroidal approach. In all mice, both eyes were injected with the same virus. One microliter of virus was administered using a 33-gauge needle and a 5-L glass syringe (Hamilton, Reno, NV).
Scotopic Electroretinography
After overnight dark adaptation, mice were anesthetized as described. This was followed by the application of one drop of 1% tropicamide (Akorn, Inc., Lake Forest, IL) to each eye for pupil dilation. Body temperature of the mouse was maintained using an animal temperature controller (ATC 1000; World Precision Instruments, Sarasota, FL). ERGs were recorded at two different light intensities (Ϫ10 and 0 dB) using (UTAS Visual Diagnostic Test System with Big Shot LED Ganzfeld; LKC Technologies, Gaithersburg, MD) using contact lens electrodes (LKC Technologies). Ten flashes were recorded and averaged for each light intensity.
Tissue Harvest, Processing, and Staining
Eyes were fixed overnight in 4% paraformaldehyde and dehydrated in 15% to 30% sucrose in 0.1 M phosphate buffer. Cornea, lens, and iris were removed, and eyecups were embedded in compound (TissueTek; Adwin Scientific Industrial, Tryon, NC). Sections measuring 14 M were taken using a cryostat (Microm 550; Thermo Scientific, Pittsburgh, PA).
GSL I.
Sections were incubated at 37°C for 10 minutes with 500 g/mL BSA in PBS followed by 100 g/mL FITC-conjugated Griffonia simplicifolia Lectin I (Isolectin B4; Vector Laboratories, Burlingame, CA) in PBS for 1 hour at 37°C. Eyecups (with retinas removed before fixation) were stained as for sections, except that blocking was performed for 30 minutes with 2.5 mg/mL BSA in PBS. Four relaxing cuts were administered before mounting on slides. Sections adjacent to those with representative GSL I stain for each of AdcmvC3 and AdcmvGFP-injected were stained for the following:
DAPI. Sections were pretreated with 0.05% Triton-PBS (PBST) for 15 minutes, followed by 1 g/mL DAPI in PBS for 5 minutes at room temperature (RT).
Rhodopsin. After blocking with 6% normal donkey serum (Jackson ImmunoResearch) in 0.25% PBST for 1 hour at RT, sections were incubated for 2.5 hours with a 1:250 dilution of mouse monoclonal 1D4 (kind gift of Robert Molday) in blocking buffer at RT, followed by a 1.5-hour incubation at RT with a 1:400 dilution of CY3-conjugated goat anti-mouse (Jackson ImmunoResearch).
GFAP.
Staining was performed as for rhodopsin, with a 1:500 dilution of rabbit polyclonal antibody anti-glial fibrillary acidic protein (GFAP; Novus Biologicals Inc, Littleton, CO) followed by a 1:500 dilution of CY3 goat anti-rabbit (Jackson ImmunoResearch), both in 6% normal goat serum.
MAC.
After blocking with 6% normal goat serum in 0.3% PBST for 30 minutes at RT, sections were stained for 2.5 hours at RT with a 1:200 dilution of rabbit anti-mouse C9 antibody (kind gift of B. Paul Morgan) in PBST, followed by 1:400 dilution of CY3-conjugated goat anti-rabbit (Jackson ImmunoResearch) at RT for 1 hour. In all cases, specificity of antibodies was determined using control antibodies of the same isotype. Sections and flatmounted eyecups were imaged using an inverted microscope (IX51; Olympus) with appropriate filters, a digital camera (Retiga 2000R FAST; QImaging), and software (QCapture Pro 5.0; QImaging).
Retinal Detachment
To produce prolonged retinal detachment without adenovirus, 6-to 8-week-old C57Bl6/J mice were injected with 1 L of 0.25% sodium hyaluronate. 31 Nine days after injection, eyes were harvested and fixed with 4% paraformaldehyde, and cryosections were stained with FITC-GSL I as described. For AdcmvC3-injected and AdcmvGFP-injected eyes, detachment was calculated by counting the number of sections with retinal detachment and multiplying by the thickness of each section (14 M). Data were analyzed using an unpaired Student's t-test.
Fluorescein Angiography
Mice were anesthetized as described, and one drop of 1% tropicamide was added to each eye. 200 L of 2.5% sodium fluorescein (Akorn, Inc.) in 1ϫ PBS was injected intraperitoneally. Eyes were coated with 2% methylcellulose and a coverslip (Corning, No.1) used to image retinal vessels using a Nikon C-PS160 dissecting microscope and appropriate filters. Eyes were monitored for 3 to 10 minutes, and images were captured (DP20; Olympus) 5 minutes after the injection of sodium fluorescein.
Quantitative RT-PCR
Eyes were harvested, and the cornea, lens, iris, and optic nerve were removed. The remaining tissue was placed in reagent (RNA Stat-60; Tel-Test, Inc., Gainesville, FL) and was homogenized using a homogenizer (AHS200; VWR, Buffalo Grove, IL). Total RNA was purified in accordance with the manufacturer's instructions and was treated for DNA contamination using a DNA-free kit (Turbo; Applied Biosystems, Foster City, CA). Total RNA was assayed for C3, VEGF, and ␤-actin using a one-step RT-PCR kit (iScript; Bio-Rad) and the Applied Biosystems assays (mouse C3, Mm00437858_m1; mouse VEGF, Mm00437304_m1; mouse ␤-actin, part 4352663) on a multicolor real-time PCR detection system (iQ5; Bio-Rad) and was analyzed using optical system software (iQ5; Bio-Rad).
Statistical Analysis
All analyses were performed using statistical software (Prism 5; GraphPad Software, Inc). In those experiments comparing three conditions, data were analyzed using a one-way ANOVA with a post-NewmanKeuls multiple comparison test for significance. All other data were analyzed using an unpaired Student's t-test. For qRT-PCR, a t-test was performed in which uninjected (for the purpose of determining significance) was given the hypothetical value of 1.0, and the significance of the fold difference of C3 and GFP was measured relative to this value.
RESULTS
C3 Expression In Vitro
C3 is a secreted protein produced as a single polypeptide precursor, pro-C3, with a predicted molecular weight of 170 kDa. Pro-C3 is cleaved intracellularly to form C3, which consists of an ␣ (107-kDa) and a ␤ (62-kDa) chain joined by disulfide bonds. 32, 33 Expression of C3 from AdcmvC3 was confirmed by immunostaining of infected HERs (Fig. 1a) . Unlike the distribution of GFP in the control AdcmvGFP-infected cells, which exhibits a diffuse presence throughout the nucleus and cytoplasm, C3 staining in the AdcmvC3-infected cells was observed to be primarily cytoplasmic. To confirm the correct size and processing of C3, a Western blot analysis was performed for both lysate and media of HERs infected with AdcmvC3 (Fig. 1b) . Under nonreducing conditions, two bands were observed in the lysate of AdcmvC3-infected cells. The approximate sizes of these bands were consistent with the presence of both C3 and its precursor, pro-C3. As expected, only the processed C3 band was observed in the media. Under reducing conditions, two bands consistent with the ␣ and the ␤ chain were observed in the media. The lysate contained a faintly higher molecular weight band consistent with nonreduced C3.
Increased Permeability of Blood Vessels in the Presence of High Levels of C3
One of the key features of a large proportion of AMD eyes is the spontaneous growth of new and leaky choroidal and retinal blood vessels. 34 Fluorescein angiography was performed on mice injected with adenoviruses expressing either C3 or GFP into the subretinal space both 8 and 14 days postinjection (PI). Although none of the eight AdcmvGFP-injected eyes (GFPinjected) tested showed any evidence of leakiness at 8 days PI, 2 of 8 (25%) AdcmvC3-injected (C3-injected) eyes showed fluorescein leakage (Fig. 2) at this time point. At 14 days PI, rapid diffusion of fluorescein into the vitreous was observed in all five (100%) of the C3-injected eyes tested (Fig. 2) , to the extent that the smaller retinal vessels were no longer visible. None of the four GFP-injected eyes tested at the 14 day time point showed any leakiness. 
C3 Overexpression Results in Extensive Proliferation of Endothelial Cells
Neovascularization is typically preceded by the proliferation and migration of vascular endothelial cells. 35 To determine the occurrence and location of endothelial cell proliferation, C3-injected or GFP-injected eyes were harvested 9 days PI, and cryosections were stained using the endothelial cell marker GSL I, isolectin B4 conjugated to FITC. Before GSL I staining, cryosections of GFP-injected eyes were assessed for GFP expression (Fig. 3a) . Although the extent of GFP expression varied between injections, expression was only observed in the RPE cell layer. After staining with GSL I, C3-injected eyes exhibited extensive staining throughout the retina compared with GFP-injected eyes (Fig. 3b) . Increased GSL I staining was seen in the region of injection in the choroid of GFP-injected compared with uninjected eyes (uninjected eyes not shown; Fig. 3b ). In addition, an increase in staining in the retina in the region of injection was observed in approximately 50% of GFP-injected mice compared with uninjected (uninjected eyes not shown) but was much less intense than in C3-injected eyes and limited to the inner retina. At higher magnification, C3-injected eyes were observed to have GSL I-positive cells at the RPE/retinal interface and in all layers of the retina (Fig. 3c) . Unlike C3-injected eyes, the increased GSL I staining in the GFP-injected eyes was restricted primarily to the choroid with some increased staining in the retina (Fig. 3c) .
A comparison of bright-field images with those of FITC-GSL I indicated a disruption of the RPE/choroid within the region of GSL I staining in C3-injected eyes (Fig. 4a) . In a number of eyes (2 of 6), we observed a migration of pigmented cells into the retina (Fig. 4a, inset) . In GFP-injected eyes, the integrity of the RPE cells was maintained, with the GSL I-positive endothelial cells not breaching the RPE (Fig. 4a) . Closer examination of the RPE/choroid of C3-injected retinas indicates a loss of RPE cells and a loss of pigment, with cells in this region staining positively for GSL I (Fig. 4b) .
Increased Retinal Detachment Is Observed in AdcmvC3-Injected Eyes
To quantitate the extent of endothelial cell proliferation in C3-injected eyes compared with that observed in GFP-injected, eyecups (with retina removed) were stained with FITC-GSL I (Fig. 5a) . The C3-injected eyecups were observed to have a significantly greater area of GSL I staining (0.73 Ϯ 0.17 mm 2 ; P Ͻ 0.05) than GFP-injected eyecups (0.03 Ϯ 0.02 mm 2 ; Fig. 5b ).
Retinal detachment was observed within the region of the most intense lectin staining in all C3-injected eyes (Fig. 3b) . Quantitation of the extent of retinal detachment observed in both GFP-injected and C3-injected mice demonstrated that the extent of retinal detachment in C3-injected retinas was significantly greater (2.6-fold; P Ͻ 0.05) than that observed in GFPinjected mice (Fig. 5c ). To determine whether the increased endothelial cell staining and disruption of the RPE/choroid observed in C3-injected mice could be accounted for solely by the greater amount of retinal detachment, 0.25% sodium hyaluronate was injected into the subretinal space of mice to induce a prolonged retinal detachment. 31 Nine days after injection, eyes were harvested and fixed, and cryosections were stained with GSL I. GSL I staining was observed almost exclusively in the inner nuclear layer (INL; Fig. 5d) , with a small number of pigmented cells at the RPE/retinal interface staining positively for GSL I. Increased magnification of the RPE/choroid in one of the sodium hyaluronate-treated eyes reveals an intact RPE layer (Fig. 5e) . No GSL I staining was observed in this region (data not shown). This observation suggested that the increased endothelial cell staining and disruption of the RPE/choroid observed in C3-injected mice was due to the expression of C3 and not to greater retinal detachment.
Photoreceptor Degeneration and Müller Cell Reactivity in C3-Injected Retinas
Staining of C3-injected retinas with the nuclear stain DAPI indicated a definitive perturbation of the outer nuclear layer (ONL), whereas the INL remained relatively undisturbed (Fig. 6a) . TUNEL staining of C3-injected retinas was negative (data not shown), indicating little or no apoptosis in the ONL. To further investigate the integrity of photoreceptors, we stained retinal sections for rhodopsin and confirmed the loss of outer segments in C3-injected eyes (Fig. 6b) . Most of the rhodopsin in GFP-injected and uninjected retinas was localized in the outer segments, with very little staining in the ONL.
In many retinal diseases, Müller cells become activated, 36 a phenomenon that can be viewed by investigating the expression of GFAP. In C3-injected eyes, the activation of Müller glia was confirmed by the observation of GFAP throughout the Müller cell, extending from the inner to the outer limiting membrane (Fig. 6c) . It is noteworthy that there were also pockets of little or no staining within this region. This staining pattern was observed only in the area of detachment. GFAP staining was observed extending into the inner plexiform and nuclear layers of the GFP-injected eyes, suggesting some reactivity in these retinas. As expected, in the uninjected retinas, GFAP staining occurred in astrocytes and Müller cell endfeet at the inner limiting membrane.
Increased C3 Expression Results in Reduced Retinal Function
Eight days after injection, scotopic electroretinograms were recorded at two different light intensities, Ϫ10 dB and 0 dB. At Quantitation of GSL I staining shows a significantly greater area of staining in AdcmvC3-injected eyecups relative to those injected with AdcmvGFP (*P Ͻ 0.05). AdcmvC3 (n ϭ 13), AdcmvGFP (n ϭ 6). (c) Retinal detachment is significantly increased (2.6-fold) in AdcmvC3-injected eyes relative to AdcmvGFP-injected (*P Ͻ 0.05). AdcmvC3 (n ϭ 5), AdcmvGFP (n ϭ 4). (d) GSL I stain of eyes injected with 0.25% sodium hyaluronate shows staining confined to endothelial cells of the inner nuclear layer, with a few pigmented cells at the RPE/retinal interface (Ͻ) staining GSL I-positive (n ϭ 3). (e) Higher magnification of the RPE/choroid of another eye injected with sodium hyaluronate shows an intact RPE cell layer. BF, bright-field; C, choroid; R, RPE; O, outer nuclear layer; I, inner nuclear layer. both intensities, b-wave amplitudes were observed to be significantly reduced in C3-injected eyes relative to GFP-injected or uninjected eyes (P Ͻ 0.05; Fig. 7) . B-wave amplitudes of C3-injected mice were reduced by 29.8% Ϯ 7.4% (0 dB) and 21.5% Ϯ 7.1% (Ϫ10 dB) when compared with GFP-injected mice. A-wave amplitudes were also observed to be significantly reduced in C3-injected eyes at the higher light intensity (0 dB) when compared with both uninjected and GFP-injected (P Ͻ 0.05) eyes (Fig. 7) but were not reduced at the lower light intensity (Ϫ10 dB). Relative to GFP-injected eyes, a-waves of C3-injected mice at 0 dB were observed to be reduced by 18.4% Ϯ 7.3%. The ratio of b-wave to a-wave was also reduced (15.5% Ϯ 3.9%) significantly in C3-injected mice when compared with GFP-injected eyes at the higher light intensity (0 dB, P Ͻ 0.05) but not at the lower light intensity (Ϫ10 dB). No significant reduction was observed in retinal function for GFPinjected compared with uninjected mice.
C3-Injected and GFP-Injected Retinas Differ in Their Expression of C3 and VEGF
Eight days after injection, C3-and GFP-injected eyes were examined for levels of C3 expression. Because of the significant amount of endothelial cell staining in C3-injected eyes, we chose to simultaneously assay for VEGF mRNA expression. Expression of C3 mRNA was significantly increased in both C3-injected eyes (57.0 Ϯ 11.8-fold; P Ͻ 0.01) and GFP-injected eyes (6.2 Ϯ 1.2-fold; P Ͻ 0.01) compared with uninjected eyes (Fig. 8) . Surprisingly, however, though C3-injected eyes showed little or no change in VEGF expression (0.97 Ϯ 0.14- fold change), GFP-injected eyes had a significant 2.6 Ϯ 0.5-fold increase in VEGF expression (P Ͻ 0.05) compared with uninjected eyes (Fig. 8) . We considered the possibility that VEGF mRNA levels might have increased at an earlier time point in C3-injected eyes, and we examined the expression of both mRNAs in whole eyecups at 3 days after injection. At this time point, we observed a significant increase in VEGF mRNA levels in C3-injected eyes of 2.98 Ϯ 0.62-fold above uninjected eyes ( Fig. 8 ; P Ͻ 0.05). The expression of VEGF in GFP-injected eyes was also significantly elevated above uninjected eyes (1.67 Ϯ 0.21-fold) at this time point (P Ͻ 0.05). Interestingly, both GFPand C3-injected eyes had significantly increased C3 mRNA expression compared with uninjected eyes at this time point ( Fig. 8 ; P Ͻ 0.05). Although the levels of C3 mRNA in GFPinjected eyes were 25.9 Ϯ 7.1-fold higher than in uninjected eyes while those of C3-injected eyes were observed to be 12.65 Ϯ 4.02-fold higher than the levels measured in uninjected eyes, this apparent difference between GFP-injected and C3-injected eyes was not significant.
Deposition of Membrane Attack Complex in AdcmvC3-Injected Retinas
To determine whether complement was activated in C3-injected eyes, retinas harvested 9 days PI were stained using a polyclonal antibody to mouse C9 (Fig. 9) . Membrane attack complex (MAC) deposition could be observed on cells at the RPE/retinal interface (Fig. 9a) ; these cells also stained positively FIGURE 7. Electroretinograms are significantly reduced in AdcmvC3-injected retinas. B-wave amplitudes of AdcmvC3-injected retinas are observed to be significantly reduced at both higher and lower light intensities relative to both AdcmvGFP-injected and uninjected, whereas a-wave amplitudes were observed to be significantly impaired only at the higher light intensity (0 dB). No significant reduction was observed in retinal function for AdcmvGFP-injected mice relative to uninjected. Data are presented as the mean Ϯ SE. n ϭ 24 for each of AdcmvGFP-and AdcmvC3-injected eyes. n ϭ 8 for uninjected. FIGURE 8. Expression of C3 mRNA, but not VEGF mRNA, is increased in AdcmvC3-injected retinas relative to uninjected. At both 3 and 8 days after injection, expression of C3 mRNA was significantly increased in AdcmvC3-injected retinas. Although no change in VEGF mRNA was observed in AdcmvC3-injected mice at 8 days after injection, a significant increase was observed at the 3-day time point. At this time point, however, a significant increase is also observed in AdcmvGFP-injected compared with uninjected retinas. Data are presented as the mean Ϯ SE. Unjd, uninjected. n ϭ 6 for AdcmvGFP and AdcmvC3; n ϭ 12 for uninjected. AdcmvGFP-injected retinas shows staining in transduced RPE cells at the site of injection but no staining in the retina. As expected after subretinal injection, some disruption of the RPE/choroid was noted at the site of injection in these mice. MAC staining was also observed in the choroid coincident with GSL I staining (not shown). BF, brightfield; C, choroid; R, RPE; O, outer nuclear layer.
for FITC-GSL I (data not shown). A higher magnification image of these GSL I-positive (GSL I staining not shown) endothelial cells at the RPE/retinal interface reveals more clearly the punctate membrane staining characteristic of MAC deposition. In addition, strong staining could be observed on the remaining outer segments of the photoreceptors (Fig. 9b) . In GFP-injected retinas, MAC staining was observed in the choroid (coincident with GSL I stain [not shown]). MAC staining was also observed on some of the AdcmvGFP-transduced RPE cells (Fig.  9c) at the site of injection but was not observed on neighboring RPE cells or in the retina.
DISCUSSION
With increasing evidence of the role of complement in the etiology of AMD and in other retinal diseases, there has been a lot of interest in studying the effects of complement dysregulation on the health of the retina. Much of the investigation has centered around the impact of inhibitors of complement, such as factor H and CD59, on the development of choroidal neovascularization in response to laser-induced damage of Bruch's membrane. 20 -22,37 A recent study of aged mice deficient in factor H has shown the deposition of C3 and C3b in the retinal vasculature, resulting in attenuation of retinal vessels and reduced blood flow. 25 We chose a more direct approach, involving the study of the consequences of local C3 overexpression in the RPE of the murine retina. We hypothesized that increased expression of C3 in murine RPE could lead to increased local C3 hydrolysis, convertase production, and complement activation. Adenovirus expressing either murine C3 or GFP from a CMV promoter was injected into the mouse subretinal space. Between 8 and 14 days after injection, eyes were analyzed to determine the effect of local exogenous C3 production.
A large proportion of patients with advanced AMD present with a spurious growth of new blood vessels from the choroid into the subretinal space, 2 and a significant subset of neovascular patients present with new vessels originating from the inner retina. 34 These immature blood vessels leak fluid, causing retinal detachment and degeneration. The relationship between complement activation and growth of new and "leaky" blood vessels in AMD eyes is unclear. In animal models it has been found that regulators of complement, such as factor H and CD59, can significantly reduce neovascularization in the laser-induced model of CNV. 20, 37 In addition, mice deficient in receptors for C3a and C5a exhibit significantly reduced laserinduced endothelial cell proliferation. 23 The anaphylatoxin C3a is known to increase vascular permeability through structural changes in the endothelium.
28 C5b-9 has been shown to affect endothelial cell proliferation and migration in models of atherosclerosis 38 and to induce the release of growth factors such as basic fibroblast growth factor. 39 Our study indicates that local exogenous expression of C3 can induce both leakiness of blood vessels and proliferation of endothelial cells in the murine retina. C3-injected eyes exhibit signs of leakage as few as 8 days after administration of the virus, a time at which a significant amount of endothelial cell staining is also observed throughout the choroid and retina. Deposition of MAC was evident on endothelial cells at the RPE-retinal interface and on remnants of the photoreceptor outer segments. The retinal detachment observed within the region of endothelial cell proliferation/migration in C3-injected retinas could occur as a result of leakage of fluid from the vasculature into the subretinal space. By 14 days after injection, all C3-injected eyes tested exhibited significant levels of leakiness.
Many AMD patients present initially with pigmentary changes in the RPE, manifesting as areas of both hyperpigmentation and hypopigmentation. 40 In approximately 40% of patients with advanced AMD, this progresses to geographic atrophy in which there are areas of RPE cell loss through which choroidal vessels are visible, with an overlying area of photoreceptor degeneration. A loss of RPE cells and pigmentation is observed in C3-injected retinas, and a loss of photoreceptor outer segments is observed in the region of endothelial cell proliferation. Transdifferentiating and migrating RPE cells have been observed in intimate association with choroidal neovascular membranes of AMD patients. 41 RPE cells have also been shown to migrate into the retina in proliferative vitreoretinopathy. 31, 42 In C3-injected retinas, pigmentary deposits could be observed in close association with cells staining positively for the endothelial cell marker GSL I, and in some cases these cells could be observed penetrating the retina.
An increase in endothelial cell staining was also observed within the region of injection in the choroid (and in some cases the retina) of GFP-injected eyes, but these proliferating endothelial cells did not penetrate the RPE. Although we have shown previously that an Ad5-expressing red fluorescent protein from a CMV promoter does not cause CNV when injected into the subretinal space, 43 the titer of the virus injected in that study was approximately 20-fold less than that administered in this study. The increase in choroidal and retinal vascular endothelial cells in GFP-injected mice is, perhaps, not surprising considering the increase in VEGF mRNA levels observed in GFP-injected mice compared with those of uninjected mice.
Increased VEGF has been observed in the eyes of AMD patients, and inhibitors of VEGF and VEGF receptors are highly effective in controlling and reducing exudative disease. 44 The anaphylatoxins C3a and C5a have been shown to induce VEGF in the mouse RPE. 23 The complex relationship between CNV development and angiogenic factors such as VEGF, bFGF, and HGF has been recently investigated in the laser-induced model of neovascularization. Of the three factors studied, VEGF was the last to be upregulated, implying a less significant role in early CNV development. 45 An increase in VEGF expression was observed in C3-injected eyes 3 days after injection but could not be attributed to C3 expression because a similar increase was observed in GFP-injected eyes. This increase in VEGF expression was not detectable in C3-injected retinas at the 8-day time point. The decline in VEGF mRNA levels observed at 8 days after injection could have been the result of significant changes in VEGF-producing cells, such as the RPE and Müller cells. 46 Although the increase in VEGF expression was not sufficient to explain the phenotype observed in C3-injected retinas, we cannot exclude a role for this growth factor in the development of the phenotype. Indeed, a potentially limiting feature of this model is that it is likely that the adenovirus itself contributes to the development of the pathology of AdcmvC3-injected retinas. AdcmvGFP-injected eyes had significantly increased endothelial cell proliferation in the choroid and retina compared with uninjected eyes. In addition, similar levels of C3 expression were observed at the 3-day time point but not the 8-day time point in both GFP-and C3-injected mice. This may not be unexpected considering that activation of the mouse complement has been observed previously for adenovirus. 47 Patients with either exudative AMD or with geographic atrophy show reduced cone and rod function as measured by ERG. 48 In one study, the reduction in scotopic a-and b-wave amplitudes was observed to correlate with increasing light intensity. 49 In our study, C3-injected eyes were observed to have significantly reduced a-wave amplitudes, as measured by scotopic ERG, at the higher light intensity but not at the lower light intensity. In addition, b-wave amplitudes were seen to be reduced at both light intensities when compared with both GFP-injected and uninjected mice. This reduction in retinal function was consistent with the loss of photoreceptor segments observed in C3-injected mice. Loss of outer segments could be attributed to vascular leakage or deposition of the MAC complex, which was observed on the remnant segments. It is worth noting that deposition of MAC at sublytic concentrations has been associated with the inhibition of apoptosis, providing a possible explanation for the absence of TUNEL staining in AdcmvC3-injected retinas. 50 No significant loss in ERG amplitudes was observed in GFP-injected mice compared with uninjected mice.
Activation of Müller cells (reactive gliosis) is a common feature of insults to the retina, 36 including retinal detachment. In fact, Müller cells have been shown to play a pivotal role in retinal detachment associated with fibrocontractive disorders such as PVR and proliferative diabetic retinopathy (PDR). 51 Because of the intimate relationship between Müller cell processes and retinal blood vessels, increased vascular permeability is a concern during reactive gliosis. In addition, in human retinas, distribution of the C3a receptor is consistent with its presence on Müller cells. 52 Altered expression and distribution of the intermediate filament protein GFAP, consistent with Müller cell activation, was observed in C3-injected eyes, and this was coincident with the region of detachment. To a lesser extent, a redistribution of GFAP was also seen in GFP-injected compared with uninjected eyes. This is perhaps not unexpected given the retinal detachment caused by a subretinal injection.
Although retinal detachment was variable in GFP-injected eyes, with some eyes showing little or no detachment, extensive retinal detachment was a consistent feature of C3-injected eyes. The changes we observed in GFAP expression and localization in the AdcmvC3-injected eyes, as well as the loss of photoreceptor outer segments, have been observed previously in models of retinal detachment. 31 However, we have shown that the proliferation of endothelial cells and the disruption of the RPE layer observed in AdcmvC3-injected mice cannot be explained by retinal detachment alone. We have not been able to determine whether the detachment is a primary effect of C3 expression or a downstream effect of endothelial cell proliferation or disruption of the RPE layer. It is possible that exogenous C3 expression may not induce retinal detachment but could prevent efficient reattachment subsequent to subretinal injection. We cannot, however, exclude the possibility that at least some of the features exclusive to C3-injected mice and not observed in GFP-injected mice (such as reduced ERGs and fluorescein leakage) occur as a result of this detachment. In future studies, we would hope to better understand the role of detachment in this model. Retinal detachment is a feature of a number of retinal diseases in which complement has been implicated, such as AMD, PVR, and PDR.
Although a number of mouse models of AMD have been described, 53 ,54 many of these are transgenic mice that require considerable aging of the mouse in addition to other special treatments, such as a high-fat diet, to recapitulate some of the pathologic conditions observed in AMD eyes and are impractical for accelerated development of therapies for this disease. We have previously described an ex vivo model of human MAC deposition on murine RPE, which we have used to test complement regulators such as CD59 and CD55. 55, 56 Although the laserinduced and VEGF-overexpression models develop quickly (within days or weeks of insult), these models are primarily representative of the exudative form of the disease, [57] [58] [59] [60] although the laser-induced CNV model has shown potential in elucidating the role of complement in CNV. 20, 37 Local increased expression of C3 in the mouse retina using an adenovirus not only recapitulates many of the pathologic conditions observed in AMD eyesneovascularization, increased vascular permeability, RPE atrophy, hypopigmentation, retinal detachment, photoreceptor degeneration, and reduced retinal function-it does so within 1 to 2 weeks of virus administration. Given the range of abnormalities recapitulated and the time course of development, this model may be useful in further elucidating the role of complement not only in AMD but in other retinal diseases such as PVR and PDR and in the development of therapies for complementmediated retinal diseases such as AMD.
